Letter | Published:

Inhibition of the LSD1 (KDM1A) demethylase reactivates the all-trans-retinoic acid differentiation pathway in acute myeloid leukemia

Nature Medicine volume 18, pages 605611 (2012) | Download Citation

Abstract

Acute promyelocytic leukemia (APL), a cytogenetically distinct subtype of acute myeloid leukemia (AML), characterized by the t(15;17)-associated PML-RARA fusion, has been successfully treated with therapy utilizing all-trans-retinoic acid (ATRA) to differentiate leukemic blasts. However, among patients with non-APL AML, ATRA-based treatment has not been effective. Here we show that, through epigenetic reprogramming, inhibitors of lysine-specific demethylase 1 (LSD1, also called KDM1A), including tranylcypromine (TCP), unlocked the ATRA-driven therapeutic response in non-APL AML. LSD1 inhibition did not lead to a large-scale increase in histone 3 Lys4 dimethylation (H3K4me2) across the genome, but it did increase H3K4me2 and expression of myeloid-differentiation–associated genes. Notably, treatment with ATRA plus TCP markedly diminished the engraftment of primary human AML cells in vivo in nonobese diabetic (NOD)-severe combined immunodeficient (SCID) mice, suggesting that ATRA in combination with TCP may target leukemia-initiating cells. Furthermore, initiation of ATRA plus TCP treatment 15 d after engraftment of human AML cells in NOD-SCID γ (with interleukin-2 (IL-2) receptor γ chain deficiency) mice also revealed the ATRA plus TCP drug combination to have a potent anti-leukemic effect that was superior to treatment with either drug alone. These data identify LSD1 as a therapeutic target and strongly suggest that it may contribute to AML pathogenesis by inhibiting the normal pro-differentiative function of ATRA, paving the way for new combinatorial therapies for AML.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Accessions

Gene Expression Omnibus

References

  1. 1.

    , & Acute myeloid leukaemia in the elderly: a review. Br. J. Haematol. 152, 524–542 (2011).

  2. 2.

    et al. Complete remission and early death after intensive chemotherapy in patients aged 60 years or older with acute myeloid leukaemia: a web-based application for prediction of outcomes. Lancet 376, 2000–2008 (2010).

  3. 3.

    & The promise of retinoids to fight against cancer. Nat. Rev. Cancer 1, 181–193 (2001).

  4. 4.

    , & Differentiation therapy of acute myeloid leukemia: past, present and future. Curr. Opin. Hematol. 16, 84–91 (2009).

  5. 5.

    et al. Retinoic acid–induced apoptosis in leukemia cells is mediated by paracrine action of tumor-selective death ligand TRAIL. Nat. Med. 7, 680–686 (2001).

  6. 6.

    , , , & Retinoids and myelomonocytic growth factors cooperatively activate RARA and induce human myeloid leukemia cell differentiation via MAP kinase pathways. Blood 105, 341–349 (2005).

  7. 7.

    et al. DNA methylation-independent loss of RARA gene expression in acute myeloid leukemia. Blood 111, 2374–2377 (2008).

  8. 8.

    et al. Genomic maps and comparative analysis of histone modifications in human and mouse. Cell 120, 169–181 (2005).

  9. 9.

    et al. Histone demethylation mediated by the nuclear amine oxidase homolog LSD1. Cell 119, 941–953 (2004).

  10. 10.

    et al. A genecentric Human Protein Atlas for expression profiles based on antibodies. Mol. Cell. Proteomics 7, 2019–2027 (2008).

  11. 11.

    et al. Lysine-specific demethylase 1 (LSD1) is highly expressed in ER-negative breast cancers and a biomarker predicting aggressive biology. Carcinogenesis 31, 512–520 (2010).

  12. 12.

    et al. Overexpression of LSD1 contributes to human carcinogenesis through chromatin regulation in various cancers. Int. J. Cancer 128, 574–586 (2011).

  13. 13.

    , , , & Histone H3 lysine 4 demethylation is a target of nonselective antidepressive medications. Chem. Biol. 13, 563–567 (2006).

  14. 14.

    et al. Inhibition of lysine-specific demethylase 1 by polyamine analogues results in reexpression of aberrantly silenced genes. Proc. Natl. Acad. Sci. USA 104, 8023–8028 (2007).

  15. 15.

    et al. HL-60 cell line was derived from a patient with FAB-M2 and not FAB-M3. Blood 71, 242–247 (1988).

  16. 16.

    et al. Direct evidence for cooperating genetic events in the leukemic transformation of normal human hematopoietic cells. Leukemia 19, 1794–1805 (2005).

  17. 17.

    , , & Differentiation-independent retinoid induction of folate receptor type β, a potential tumor target in myeloid leukemia. Blood 96, 3529–3536 (2000).

  18. 18.

    & Major deletions in the gene encoding the p53 tumor antigen cause lack of p53 expression in HL-60 cells. Proc. Natl. Acad. Sci. USA 82, 790–794 (1985).

  19. 19.

    et al. A small molecule screening strategy with validation on human leukemia stem cells uncovers the therapeutic efficacy of kinetin riboside. Blood 119, 1200–1207 (2012).

  20. 20.

    , , , & Induction of differentiation in blast cells and leukemia colony-forming cells from patients with acute myeloid leukemia. Blood 75, 721–729 (1990).

  21. 21.

    & Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat. Med. 3, 730–737 (1997).

  22. 22.

    et al. Cytokine stimulation of multilineage hematopoiesis from immature human cells engrafted in SCID mice. Science 255, 1137–1141 (1992).

  23. 23.

    et al. Revised map of the human progenitor hierarchy shows the origin of macrophages and dendritic cells in early lymphoid development. Nat. Immunol. 11, 585–593 (2010).

  24. 24.

    , , , & Individual stem cells with highly variable proliferation and self-renewal properties comprise the human hematopoietic stem cell compartment. Nat. Immunol. 7, 1225–1233 (2006).

  25. 25.

    et al. A retroviral mutagenesis screen reveals strong cooperation between Bcl11a overexpression and loss of the Nf1 tumor suppressor gene. Blood 113, 1075–1085 (2009).

  26. 26.

    et al. Antiapoptotic microenvironment of acute myeloid leukemia. J. Immunol. 173, 6745–6752 (2004).

  27. 27.

    et al. RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia. Nature 478, 524–528 (2011).

  28. 28.

    et al. The lysine demethylase LSD1 (KDM1) is required for maintenance of global DNA methylation. Nat. Genet. 41, 125–129 (2009).

  29. 29.

    , , , & Epigenomics of leukemia: from mechanisms to therapeutic applications. Epigenomics 3, 581–609 (2011).

  30. 30.

    et al. Biochemical, structural, and biological evaluation of tranylcypromine derivatives as inhibitors of histone demethylases LSD1 and LSD2. J. Am. Chem. Soc. 132, 6827–6833 (2010).

  31. 31.

    et al. Identification of cell-active lysine specific demethylase 1-selective inhibitors. J. Am. Chem. Soc. 131, 17536–17537 (2009).

  32. 32.

    , , & Comparative analysis of small molecules and histone substrate analogues as LSD1 lysine demethylase inhibitors. J. Am. Chem. Soc. 132, 3164–3176 (2010).

  33. 33.

    et al. Novel oligoamine analogues inhibit lysine-specific demethylase 1 and induce reexpression of epigenetically silenced genes. Clin. Cancer Res. 15, 7217–7228 (2009).

  34. 34.

    et al. (Bis)urea and (bis)thiourea inhibitors of lysine-specific demethylase 1 as epigenetic modulators. J. Med. Chem. 53, 5197–5212 (2010).

  35. 35.

    Monoamineoxidase inhibitors. in Medical Toxicology (ed. Dart, R.C.) 823–833 (Lippincott Williams and Wilkins, Philadelphia, Pennsylvania, USA, 2003).

  36. 36.

    , , & Reversible cell surface expression of CD38 on CD34-positive human hematopoietic repopulating cells. Exp. Hematol. 35, 1429–1436 (2007).

Download references

Acknowledgements

T.S., L.H., K.P. and A.Z. were supported by a Specialist Programme Grant from Leukaemia and Lymphoma Research. T.S., L.H., K.P. and A.Z. were also supported in part by the Samuel Waxman Cancer Research Foundation. S.G. and C.M.-T. were supported by the Interdisziplinäres Zentrum für Klinische Forschung (IZKF) and the Deutsche Forschungsgemeinschaft (1328/6-1, 8-1 and 9-1). W.C.C., L.J., J.C.Y.W. and J.E.D. were supported by the Cancer Stem Cell Consortium with funding from the Government of Canada through Genome Canada and the Ontario Genomics Institute (OGI-047) and through the Canadian Institute of Health Research (CSC-105367), as well as with funding from Canadian Institutes for Health Research (CIHR), the Canadian Cancer Society Research Institute, the Terry Fox Foundation; Genome Canada through the Ontario Genomics Institute; Ontario Institute for Cancer Research with funds from the province of Ontario; and a Canada Research Chair. W.C.C., L.J., J.C.Y.W. and J.E.D. were also funded in part by the Ontario Ministry of Health and Long Term Care (OMOHLTC). The views expressed here do not necessarily reflect those of the OMOHLTC. R.A.C. Jr. was supported by a National Cancer Institute Grant (CA51085). The authors would like to thank D. Leongamornlert, L. Jasnos and S. Bashir for valuable discussions on the interpretation of the ChIP-Seq data and the statistical analyses. The authors would also like to thank M. Greaves for support and critical reading of the manuscript.

Author information

Author notes

    • Weihsu Claire Chen
    • , Stefanie Göllner
    •  & Louise Howell

    These authors contributed equally to this work.

Affiliations

  1. Division of Molecular Pathology, Institute of Cancer Research, Sutton, UK.

    • Tino Schenk
    • , Louise Howell
    • , Kevin Petrie
    •  & Arthur Zelent
  2. Division of Stem Cell and Developmental Biology, Campbell Family Cancer Research Institute, Ontario Cancer Institute and Princess Margaret Hospital, University Health Network, Toronto, Ontario, Canada.

    • Weihsu Claire Chen
    • , Liqing Jin
    • , Andreea C Popescu
    • , Jean C Y Wang
    •  & John E Dick
  3. Department of Medicine, Hematology and Oncology and Interdisciplinary Centre for Clinical Research (IZKF), University of Münster, Münster, Germany.

    • Stefanie Göllner
    •  & Carsten Müller-Tidow
  4. Institute of Medical Informatics, University of Münster, Münster, Germany.

    • Katja Hebestreit
    • , Hans-Ulrich Klein
    •  & Martin Dugas
  5. Heath Park, School of Medicine, Cardiff University, Cardiff, UK.

    • Alan Burnett
  6. Centre for Cancer Research and Cell Biology, School of Medicine, Dentistry and Biomedical Sciences, Queen's University, Belfast, UK.

    • Ken Mills
  7. Department of Oncology, Johns Hopkins University, Baltimore, Maryland, USA.

    • Robert A Casero Jr
  8. Progen Pharmaceuticals, Inc., Palo Alto, California, USA.

    • Laurence Marton
  9. Department of Pharmaceutical and Biomedical Sciences, Medical University of South Carolina, Charleston, South Carolina, USA.

    • Patrick Woster
  10. Department of Medicine, University of Toronto, Toronto, Ontario, Canada.

    • Mark D Minden
    •  & Jean C Y Wang
  11. Department of Molecular Genetics, University of Toronto, Toronto, Ontario, Canada.

    • John E Dick

Authors

  1. Search for Tino Schenk in:

  2. Search for Weihsu Claire Chen in:

  3. Search for Stefanie Göllner in:

  4. Search for Louise Howell in:

  5. Search for Liqing Jin in:

  6. Search for Katja Hebestreit in:

  7. Search for Hans-Ulrich Klein in:

  8. Search for Andreea C Popescu in:

  9. Search for Alan Burnett in:

  10. Search for Ken Mills in:

  11. Search for Robert A Casero in:

  12. Search for Laurence Marton in:

  13. Search for Patrick Woster in:

  14. Search for Mark D Minden in:

  15. Search for Martin Dugas in:

  16. Search for Jean C Y Wang in:

  17. Search for John E Dick in:

  18. Search for Carsten Müller-Tidow in:

  19. Search for Kevin Petrie in:

  20. Search for Arthur Zelent in:

Contributions

T.S. performed cell drug treatments, ChIP-Seq, quantitative PCR, RNAi and western blotting; L.H. performed cell drug treatments, FACS, the superoxide assay, immunohistochemical staining and light microscopy; S.G. and C.M.-T. performed ChIP-Seq and primary AML sample drug treatments; W.C.C., L.J., A.C.P., J.C.Y.W. and J.E.D. performed in vivo treatments of AML in NOD-SCID and NSG mice; K.H., H.-U.K. and M.D. performed bioinformatic analyses of expression microarray and ChIP-Seq data; A.B., K.M. and M.D.M. isolated primary AML samples; P.W., L.M. and R.A.C. Jr. collaborated on the 2d LSD1 inhibitor; T.S., K.P. and A.Z. designed the study and analyzed the data; K.P. and A.Z. wrote the paper. All authors discussed the results and commented on the manuscript.

Competing interests

L.M. was employed by Progen Pharmaceuticals. R.A.C. and P.W. have received funding from Progen Pharmaceuticals.

Corresponding author

Correspondence to Arthur Zelent.

Supplementary information

PDF files

  1. 1.

    Supplementary Text and Figures

    Supplementary Figures 1–11, Supplementary Tables 1–3 and Supplementary Methods

Excel files

  1. 1.

    Supplementary Data 1

  2. 2.

    Supplementary Data 2

About this article

Publication history

Received

Accepted

Published

DOI

https://doi.org/10.1038/nm.2661

Further reading